Roche Q1 Group Sales Up 11% At CER

Swiss drug major Roche Holding AG (RHHBY) reported that its first quarter group sales increased 11% at constant exchange rates and 10% in Swiss francs year-over-year to 16.4 billion francs.

Diagnostics Division sales grew 24% at constant exchange rates due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.

At constant exchange rates, Pharmaceuticals Division sales increased by 6% to 11.2 billion francs. Newly launched medicines to treat severe diseases continued their strong growth, including Ronapreve (COVID-19; mainly in Japan), Ocrevus (multiple sclerosis), Hemlibra (haemophilia), Evrysdi (spinal muscular atrophy) and Phesgo (breast cancer).

The company confirmed its outlook for its fiscal year 2022.

The company still expects annual core earnings per share to grow in the low- to mid-single digit range (at constant exchange rates), including the accretive effect of the 2021 share repurchase. Sales are expected to be stable or grow in the low-single digits at constant exchange rates.

Roche expects to increase its dividend in Swiss francs further.

Roche anticipates sales of COVID-19 medicines and diagnostics to decrease by approximately 2 billion francs to around 5 billion francs, and sales losses to biosimilars in the current year to be roughly 2.5 billion francs. Excluding the effects, Group sales are expected to grow in the high-single digit range.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT